Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK

Nav

General Info

Geography

Belgium (BEL)

Italy (ITA)

Sweden (SWE)

United Kingdom (GBR)

Coverage type

Country

Time period covered

01/2009 - 12/2010

Data type

Scientific literature

Keywords

HIV and AIDS, Health care costs, Health care expenditures

Citation

Authors

Moeremans K, Annemans L, Löthgren M, Allegri G, Wyffels V, Hemmet L, Caekelbergh K, Smets E

Journal

Pharmacoeconomics

Volume

28 Suppl 1

Pages

107-28

Publication year

2010

Suggested citation

Moeremans K, Annemans L, Löthgren M, Allegri G, Wyffels V, Hemmet L, Caekelbergh K, Smets E. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics. 2010; 28 Suppl 1: 107-28.

DOI

10.2165/11587480-000000000-00000

PMID

21182347

GHDx Entry last modified on: Apr 10, 2023

Header sites

Search form

Main menu

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK

Nav